News
New 3D imaging method offers hope for IVF patients
New approach could transform current blastocyst selection methods and open avenues for increased pregnancy rates, say researchers
A novel 3D imaging model designed to identify features of blastocysts, the early stage of development for an implanted embryo, offers hope for thousands of IVF patients, a new study has shown.
The shape and structure of blastocysts can predict the success of a pregnancy, aiding blastocyst selection for IVF. However, selecting the right embryo or blastocyst remains a challenge within IVF.
This new technique, introduced at the ESHRE annual meeting in Amsterdam, could “transform” current blastocyst selection methods and open avenues for increased pregnancy rates.
“Traditionally, the quality of blastocysts is assessed using 2D methods that lack depth and comprehensive indicators,” explained Dr Bo Huang, embryologist at the Reproductive Medicine Center of Tongji Hospital in China and lead author of the study.
“Although some 3D methods exist, they aren’t practical or safe for clinical use. This study bridges that gap by introducing a clinically applicable 3D evaluation method and reveals previously unrecognised spatial features of blastocysts indicative of outcomes.”
The research, published in the journal Human Reproduction, included women under 40 years old with a uterine lining of 7-16mm and no more than one previous embryo transfer failure. Using a device called EmbryoScope+, researchers took detailed images of 2,141 frozen-thaw single blastocysts.
Advanced technology was used to create 3D models of these blastocysts, capturing detailed information about their outer layer and inner cell mass. These models were then analysed to find new blastocyst features and determine how these features relate to successful pregnancies.
The study tested the model by comparing it with fluorescence imaging of human blastocysts and achieved over 90 per cent accuracy. Key measurements identified captured the blastocyst’s size, shape and cell characteristics.
Parameters related to size, such as overall volume, cavity volume, and surface area were found to be linked to higher pregnancy rates, and specific features of the inner cell mass and outer layer were also strongly associated with better pregnancy outcomes.
“These results match what we see in clinical outcomes, but we couldn’t previously measure these,” said Huang. “This study shows that the 3D shape of the blastocyst’s inner cell mass, its position, and how the surrounding cells are arranged can be important indicators of success, which we didn’t know before.”
Moving forward, the research team plans to collaborate with multiple reproductive centres worldwide to validate these findings. The ultimate goal, they said, is to make the 3D evaluation of blastocysts a standard part of clinical practice.
Professor Dr Anis Feki, chair-elect of ESHRE, said: “While the new 3D imaging model for blastocyst evaluation shows great promise in improving embryo selection for IVF, it is essential to validate these findings through further studies and collaborations.
“This method could potentially enhance IVF outcomes, but its clinical application should be approached with careful consideration.”
To receive the Femtech World newsletter, sign up here.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Fertility
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Wellness2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Entrepreneur4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







1 Comment